Literature DB >> 33433069

Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH.

Tzu-Fei Wang1, Robert S Makar2, Darko Antic3,4, Jerrold H Levy5, James D Douketis6, Jean M Connors7, Marc Carrier1, Jeffrey I Zwicker8.   

Abstract

Patients with acute leukemia frequently develop thrombocytopenia and hemostatic complications caused by coagulopathy. Coagulopathy complicates the management of these patients and can lead to significant morbidity and mortality. This guidance document aims to review and provide guidance on the management of hemostatic complications in adult patients with acute leukemia, addressing four main issues, including platelet transfusion, disseminated intravascular coagulation, L-asparaginase-related hypofibrinogenemia, and the use of antifibrinolytic agents.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  acute leukemia; guidance; hemostatic complications

Mesh：

Substances：

Year:  2020        PMID： 33433069      PMCID： PMC7909744          DOI： 10.1111/jth.15074

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


  71 in total

1.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

2.  Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia.

Authors:  Samo Zver; Dusan Andoljsek; Peter Cernelc
Journal:  Eur J Haematol       Date:  2004-06       Impact factor: 2.997

3.  Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series.

Authors:  Ariela Marshall; Ang Li; Adrienne Drucker; Walter Dzik
Journal:  Hematol Oncol       Date:  2015-02-02       Impact factor: 5.271

4.  All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia.

Authors:  J E Brown; A Olujohungbe; J Chang; W D Ryder; G R Morganstern; R Chopra; J H Scarffe
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

5.  Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.

Authors:  Masamitsu Yanada; Tadashi Matsushita; Norio Asou; Yuji Kishimoto; Motohiro Tsuzuki; Yasuhiro Maeda; Kentaro Horikawa; Masaya Okada; Shigeki Ohtake; Fumiharu Yagasaki; Tadashi Matsumoto; Yukihiko Kimura; Katsuji Shinagawa; Masako Iwanaga; Yasushi Miyazaki; Ryuzo Ohno; Tomoki Naoe
Journal:  Eur J Haematol       Date:  2007-01-16       Impact factor: 2.997

6.  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.

Authors: 
Journal:  N Engl J Med       Date:  1997-12-25       Impact factor: 91.245

7.  Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia.

Authors:  G Avvisati; J W ten Cate; H R Büller; F Mandelli
Journal:  Lancet       Date:  1989-07-15       Impact factor: 79.321

8.  International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia.

Authors:  Mirjana Mitrovic; Nada Suvajdzic; Andrija Bogdanovic; Nada Kraguljac Kurtovic; Aleksandra Sretenovic; Ivo Elezovic; Dragica Tomin
Journal:  Med Oncol       Date:  2013-01-31       Impact factor: 3.064

Review 9.  Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review.

Authors:  Katerina Pavenski; Paolo Rebulla; Rene Duquesnoy; Chee Loong Saw; Sherrill J Slichter; Susano Tanael; Nadine Shehata
Journal:  Transfusion       Date:  2013-04-03       Impact factor: 3.157

10.  Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.

Authors:  Ashish Dixit; Tathagat Chatterjee; Pravas Mishra; Meganathan Kannan; Dharma R Choudhry; Manoranjan Mahapatra; V P Choudhry; Renu Saxena
Journal:  Clin Appl Thromb Hemost       Date:  2007-07       Impact factor: 2.389
View more
  4 in total

Review 1.  Can fibrinolytic therapy be clinically useful in severe pneumonia caused by COVID-19?

Authors:  Rafael Bornstein; José Antonio Páramo
Journal:  J Thromb Thrombolysis       Date:  2020-08-12       Impact factor: 2.300

2.  Case Report: ANXA2 Associated Life-Threatening Coagulopathy With Hyperfibrinolysis in a Patient With Non-APL Acute Myeloid Leukemia.

Authors:  Leo Ruhnke; Friedrich Stölzel; Lisa Wagenführ; Heidi Altmann; Uwe Platzbecker; Sylvia Herold; Andreas Rump; Evelin Schröck; Martin Bornhäuser; Johannes Schetelig; Malte von Bonin
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

Review 3.  Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.

Authors:  Claire Comerford; Siobhan Glavey; Jamie M O'Sullivan; John Quinn
Journal:  Cancer Drug Resist       Date:  2022-03-07

4.  Application of Rotational Thromboelastometry in Patients with Acute Promyelocytic Leukemia.

Authors:  Nikica Sabljic; Nikola Pantic; Marijana Virijevic; Zoran Bukumiric; Tina Novakovic; Zlatko Pravdic; Jovan Rajic; Ana Vidovic; Nada Suvajdzic; Mark Jaradeh; Jawed Fareed; Darko Antic; Mirjana Mitrovic
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.